About Endocarditis Clinical Trials (Click to Open)

Join Clinical Trials for Endocarditis

Clinical Trials for EndocarditisGeneral Purpose:  

Endocarditis refers to infection of the inner lining of the heart, also known as the endocardium. It is generally caused by a bacterial infection that spreads from another part of the body to the heart. If it is untreated, it can damage – and even destroy – the valves of the heart, and can result in life-threatening side effects.

Surgery may be required to treat severe cases of endocarditis, but thankfully it can generally be managed with the use of antibiotic therapy. Fortunately, endocarditis rarely affects individuals who have healthy hearts; however, if you or a loved one has a condition that puts you at an increased risk for endocarditis (such as a damaged or artificial heart valve), clinical trials for endocarditis may be of considerable interest and value to you.

Fortunately, researchers are hard at work investigating new methods of treating endocarditis – both from a surgical standpoint as well as a medicinal one – and great strides are being made every day toward this goal.

In addition, research is also looking at better ways to characterize and diagnose endocarditis, as well as improving the rehabilitation and long-term outcome of patients who are treated for endocarditis.

What Will Clinical Trials for Endocarditis Be Like?

The types of tests and assessments used in endocarditis clinical trials will ultimately Clinical Trials for Endocarditisdepend on the specific nature of the study and what aspects of endocarditis are being investigated. Provided below is a list of frequent procedures and tests used to evaluate the heart, heart functioning, and its impact on the body in general, many of which may be incorporated for use in clinical trials: 

  • Physical exam
  • Blood tests to identify bacteria in the bloodstream, as well as to identify the presence of conditions such as anemia (low red blood cells), which can further support the diagnosis of endocarditis.
  • Echocardiography (“echo”): a painless procedure that uses ultrasound to create moving pictures of your heart, which allow doctors to see its size, shape, and how well it is working. During a procedure known as transesophageal echocardiography, a long, thin ultrasound probe is guided down the throat into the esophagus, which is directly behind the heart, in order to obtain more detailed pictures.
  • Electrocardiogram (EKG, or ECG): a straightforward and painless procedure that records the electrical activity of the heart. This test tells doctors how fast your heart is beating, the regularity (or irregularity) of your heart rhythm, and strength and timing of the electrical signals that constantly pass through the heart.
  • Chest x-ray
  • Computed tomography (CT scan, or “CAT scan”) or magnetic resonance imaging (MRI) scans: these are non-invasive imaging procedures, similar to an x-ray, that allow doctors to take detailed pictures of your heart.
  • Blood tests to evaluate the effectiveness or chemical properties of a medication, if you are participating in a clinical trial that is investigating the use of a new drug.
  • Pain and quality of life assessments, as well as exercise diaries, may also be required in some studies, depending on the research question being studied.

Typical Protocol for Clinical Trials for Endocarditis: 

Specific examples of Clinical Trials for Endocarditis for the various forms of cardiomyopathy might include the following:

  • A randomized clinical trial that investigates the use of orally-administered antibiotic therapy to the standard method of administering antibiotic therapy (intravenously, or through an IV) to determine if one method is more effective at reducing the need for later surgery, clot formation, and relapse of infection in individuals with endocarditis.  
  • A study designed to determine if transesophageal echocardiography or standard CT scans are more effective at visualizing endocarditis.
  • A randomized clinical trial to determine if a newly developed antibiotic is more effective than standard antibiotic therapy plus placebo at a) treating the bacterial causes of endocarditis and b) reducing the associated side effects of treatment.
  • A randomized clinical trial to determine if a new state-of-the-art surgical treatment for endocarditis is more effective at reducing endocarditis-related death than standard surgical treatment. 

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” treatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the Clinical Trials for Endocarditisinvestigational treatment or the standard treatment.

On occasion, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo (such as the third clinical trial example given above). Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug or therapy is being investigated, the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

It is important to know that placebo-only trials are only conducted when scientifically necessary and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular disease or condition.  

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors, including Clinical Trials for Endocarditisyour history of heart disease, treatment history, and a variety of clinical findings. Therefore, it is important to know many details pertaining to your specific diagnosis when searching for clinical trials. Examples of the details you may want to have on hand include: 

  • Your prior history of heart disease
  • Your prior history of treatment for heart disease (including any surgeries, procedures, and medications)
  • Your current medications (including aspirin), vitamins, and dietary supplements
  • Your most recent blood pressure, cholesterol, and triglyceride (i.e., lipid) levels 

Suggested Search Terms:

“endocarditis rehabilitation,” “endocarditis risk factors,” “endocarditis prevention,” “endocarditis treatment,” “endocarditis antibiotics,” “endocarditis surgery,” “endocarditis side effects,” and “endocarditis quality of life,” “Clinical Trials for Endocarditis.”

Current Search Term:


Add Comments or Questions

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Conditions:   Staphylococcus Aureus Bacteremia;   Right-Sided Staphylococcus Aureus Endocarditis
Interventions:   Biological: CF-301;   Drug: Placebo
Sponsor:   ContraFect
Not yet recruiting - verified May 2017

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Condition:   Infective Endocarditis, Bacteremia
Interventions:   Drug: Dalbavancin;   Drug: Standard of Care
Sponsor:   Allergan
Not yet recruiting - verified May 2017

Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis

Conditions:   Bacteremia;   Infective Endocarditis
Intervention:   Procedure: Blood Culture
Sponsor:   Central Hospital, Nancy, France
Not yet recruiting - verified April 2017

The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials

Condition:   Endocarditis
Intervention:   Drug: 99mTc-Leukoscan® scintigraphy
Sponsor:   Hospices Civils de Lyon
Not yet recruiting - verified April 2017

Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis

Conditions:   Endocardits, Bacterial;   Opioid-use Disorder;   Buprenorphine;   Outpatient Parenteral Antibiotic Therapy
Interventions:   Drug: Buprenorphine/naloxone;   Other: Outpatient parenteral antibiotic therapy
Sponsor:   Laura Fanucchi
Recruiting - verified May 2017

Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis

Condition:   Infective Endocarditis
Sponsor:   National Institute of Cardiology, Laranjeiras, Brazil
Recruiting - verified October 2016

Infective Endocarditis in the Elderly

Condition:   Infective Endocarditis
Sponsors:   Central Hospital, Nancy, France;   Fondation Cœur et Recherche
Recruiting - verified September 2016

Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis

Condition:   Infective Endocarditis (IE)
Intervention:   Other: determine the prognosis of threated patients according to the clinical care pathway.
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified August 2016

Research Interest Antiphospholipid in Predicting Embolic Risk During Infective Endocarditis

Condition:   Infective Endocarditis
Sponsor:   Central Hospital, Nancy, France
Recruiting - verified August 2016

Etiology of Endocarditis in Negative Blood Cultures

Condition:   Infective Endocarditis (IE)
Intervention:   Other: blood samples
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified June 2016

An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures

Conditions:   Bacteraemia;   Endocarditis
Interventions:   Drug: Amoxicillin;   Drug: Amoxicillin-Potassium Clavulanate
Sponsors:   University of Santiago de Compostela;   Hospital Clinico Universitario de Santiago
Recruiting - verified March 2017

Inflammatory Mediator Profiles During Heart Valve Replacement Surgery

Conditions:   Infective Endocarditis;   Valvular Heart Disease
Interventions:   Procedure: Blood sample collection;   Other: Assessment of signs of organ dysfunction
Sponsors:   Jena University Hospital;   Thermo Fisher Scientific
Recruiting - verified October 2016

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus

Condition:   Infective Endocarditis
Interventions:   Drug: Amoxicillin;   Procedure: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
Sponsor:   University Hospital, Tours
Recruiting - verified February 2017

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus

Condition:   Infective Endocarditis
Interventions:   Drug: Levofloxacin;   Drug: Rifampicin;   Procedure: Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Sponsor:   University Hospital, Tours
Recruiting - verified February 2017

Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis

Conditions:   Endocarditis;   Thrombosis
Intervention:   Other: 99mTc-Annexin V-128 SPECT
Sponsors:   Institut National de la Santé Et de la Recherche Médicale, France;   Advanced Accelerator Applications
Recruiting - verified July 2016

Endocarditis Registry of the University Hospital of Cologne (ER-UHC)

Condition:   Infective Endocarditis
Sponsor:   University of Cologne
Recruiting - verified May 2017

18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis

Condition:   Infective Endocarditis
Intervention:   Procedure: 18-FDG PET/CT scan
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified April 2017

Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection

Conditions:   Infections of the Implanted Material;   Endocarditis
Intervention:   Device: Whole-body 18FDG-PET-CT scan
Sponsor:   University Hospital, Bordeaux
Recruiting - verified January 2017

Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure

Conditions:   Renal Failure;   Critical Care;   Gram Positive Bacteria
Intervention:   Drug: Daptomycin
Sponsor:   Poitiers University Hospital
Completed - verified October 2016

The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery

Condition:   Acute Kidney Injury
Interventions:   Drug: sodium bicarbonate;   Drug: Saline
Sponsor:   Yonsei University
Recruiting - verified June 2016

CopenHeart IE - Integrated Rehabilitation of Patients Treated for Infective Endocarditis

Condition:   Infective Endocarditis
Interventions:   Other: Integrated rehabilitation;   Other: Usual follow-up
Sponsors:   Rigshospitalet, Denmark;   University Hospital, Gentofte, Copenhagen;   Copenhagen Trial Unit, Center for Clinical Intervention Research
Recruiting - verified November 2016

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Condition:   Staphylococcal Infection
Interventions:   Drug: Daptomycin 4 mg/kg;   Drug: Comparator: vancomycin;   Drug: Daptomycin 6 mg/kg
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2017

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Conditions:   Endocarditis, Bacterial;   Infective Endocarditis
Interventions:   Drug: daptomycin;   Drug: vancomycin
Sponsor:   Cubist Pharmaceuticals LLC
Terminated - verified February 2017

Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.

Condition:   Endocarditis, Bacterial
Intervention:   Drug: Daptomycin
Sponsor:   Weill Medical College of Cornell University
Terminated - verified April 2017

Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

Conditions:   Bacterial Endocarditis;   Bacteremia
Intervention:   Drug: daptomycin
Sponsor:   Cubist Pharmaceuticals LLC
Completed - verified February 2017

Refine Your Search Advanced Search